Sabiad

Executive Summary

Sabiad, a Dutch biotech spin-off from the University Medical Center Groningen (UMCG), is pioneering theranostic solutions for bacterial infections, with an initial focus on Staphylococcus aureus (SA). The company leverages proprietary antibody-based tracers for real-time detection and targeted treatment of infections, aiming to disrupt biofilms, improve patient outcomes, and reduce reliance on broad-spectrum antibiotics. Founded in 2019 and based in Amsterdam, Sabiad operates in the diagnostics category and is privately held. While the company has not disclosed funding rounds or valuation, its technology platform addresses a critical unmet need in infectious disease management—precise, real-time identification and treatment of bacterial infections, which could help combat antibiotic resistance. The theranostic approach combines diagnostic imaging with therapy, potentially reducing unnecessary antibiotic use and improving surgical outcomes.

Upcoming Catalysts (preview)

• Q4 2026Initiation of First-in-Human Clinical Trial60% success
• Q2 2026Series A Funding Round Announcement70% success
• Q3 2026Partnership with a Major Pharmaceutical Company40% success